This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

14 Jun 2012

Upsher-Smith to Acquire Proximagen

The acquisition provides Upsher-Smith Laboratories with expanded R&D capabilities.

Upsher-Smith Laboratories agreed to acquire Proximagen, a company focused on therapeutics for central nervous system (CNS) diseases.


Upsher-Smith intends to integrate operations in Cambridge and London, U.K. The acquisition provides Upsher-Smith with expanded R&D capabilities. Proximagen’s pipeline contains a number of programs in various stages of development across a breadth of therapeutic classes including CNS, inflammation, oncology, and ophthalmology. Its most advanced candidate is Phase II-stage PRX00933 for obesity and type 2 diabetes. In Phase I/II are naluzotan and tonabersat for treatment of refractory epilepsy patients and sabcomeline for cognition in schizophrenia.


Upsher-Smith’s central nervous system pip

Related News